At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Neuroendocrine Tumors. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melanoma and for metastatic non-small cell lung cancer. However, it is not approved for treatment of metastatic high-grade neuroendocrine tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroendocrine Tumors
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartOct 2016
Primary CompletionFeb 2018
Study CompletionMar 2020
TodayJul 2026
First PostedOct 20, 2016
Enrollment StartOct 26, 2016
Primary CompletionFeb 1, 2018
Study CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.7 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks